Abstract:Abstract Two treatment strategies, tyrosine kinase inhibitors (TKIs), and immune checkpoint inhibitors (ICIs), have improved long-term survival for patients with advanced non-small cell lung cancer (NSCLC). However, choosing the right treatment is challenging as the currently approved biomarkers for treatment decision are biopsy based: activating mutations in epidermal growth factor receptor (EGFR) and expression of programmed death-ligand 1 (PD-L1). Biopsies are subject to false negatives because of sampling bias, and they can change during therapy rendering that treatment ineffective. Therefore, there is a compelling need to identify additional biomarkers that reflect the entire tumor and can be obtained non-invasively to help guide therapy choice. Herein, we test the hypothesis that EGFR mutation and PD-L1 expression status can be captured by analysis of 18F-FDG-PET/CT images with artificial intelligence (AI) algorithms. These can be used in combination to construct a treatment decision support system based on their association with clinical outcomes following treatment with TKIs or ICIs. This retrospective study enrolled 837 NSCLC patients from four international institutions: Shanghai Pulmonary Hospital (SPH), the Fourth Hospital of Hebei Medical University (HBMU), the Fourth Hospital of Harbin Medical University (HMU), and the H. Lee Moffitt Cancer Center (HLM). Two residual-convolutional-network (ResCNN) models to predict EGFR mutation and PD-L1 positive status were trained (N=429) and validated (N=187) with PET/CT images and clinical data of 616 patients from SPH and HBMU, and then tested using external HMU test cohort with EGFR mutation status (N=65) and HLM test cohort with PD-L1 expression status (N=85). Subsequently, the generated EGFR and PD-L1 deep learning scores (EGFR-DLS and PDL1-DLS) of the ResCNN models were further associated with progression-free survival (PFS) in HMU EGFR-TKI-treated patients (N=67) and HLM ICI-treated patients (N=149). The EGFR-DLS and PDL1-DLS demonstrated high accuracy in EGFR mutation status prediction with AUCs of 0.86 (95%CI: 0.83-0.90), 0.83 (95%:0.78-0.88) and 0.81(95%CI: 0.72-0.91), and in PD-L1 positive status discrimination with AUCs of 0.89 (95%CI: 0.84-0.94), 0.84 (95%CI: 0.76-0.92) and 0.82 (95%CI: 0.74-0.89) for training, validation and external test cohorts, respectively. Patient responses to TKI and ICI were found to be reciprocal: for patients with high EGFR-DLS, EGFR-TKI treatment was significantly associated with longer PFS regardless of PDL1-DLS (low PDL1-DLS, p=0.006; high PDL1-DLS, p=0.067); for patients with low EGFR-DLS, ICI treatment was significantly associated with longer PFS (p=0.007) in particular those patients with high PDL1-DLS. Therefore, the combination of EGFR-DLS and PDL1-DLS could be used as an alternative non-invasive Decision Support Tool for NSCLC. Citation Format: Wei Mu, Lei Jiang, Jianyuan Zhang, Yu Shi, Jhanelle E. Gray, Xinming Zhao, Xilin Sun, Jie Tian, Matthew B. Schabath, Robert J. Gillies. Radiomics and AI-based treatment decision support for non-small cell lung cancer [abstract]. In: Proceedings of the AACR Virtual Special Conference on Artificial Intelligence, Diagnosis, and Imaging; 2021 Jan 13-14. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(5_Suppl):Abstract nr PR-03.

Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

Predicting EGFR and PD-L1 Status in NSCLC Patients Using Multitask AI System Based on CT Images

Prediction of oncogene mutation status in non-small cell lung cancer: A systematic review and meta-analysis with a special focus on artificial-intelligence-based methods

Prediction of Epidermal Growth Factor Receptor Mutation Subtypes in Non-Small Cell Lung Cancer From Hematoxylin and Eosin-Stained Slides Using Deep Learning

Mining whole-lung information by artificial intelligence for predicting EGFR genotype and targeted therapy response in lung cancer: a multicohort study

Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer

Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC

Abstract PR-03: Radiomics and AI-based Treatment Decision Support for Non-Small Cell Lung Cancer

AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer

Deep Learning to Predict EGFR Mutation and PD-L1 Expression Status in Non-Small-Cell Lung Cancer on Computed Tomography Images

Nomograms To Predict The Presence Of Egfr Mutations And Alk Rearrangements In Non-Small-Cell Lung Carcinoma

A Large-Scale Cross-Sectional Study of ALK Rearrangements and EGFR Mutations in Non-Small-cell Lung Cancer in Chinese Han Population.

A Computed Tomography-Derived Radiomics Approach for Predicting Uncommon EGFR Mutation in Patients With NSCLC

Prediction of Driver Gene Matching in Lung Cancer NOG/PDX Models Based on Artificial Intelligence

Artificial intelligence-based personalized survival prediction using clinical and radiomics features in patients with advanced non-small cell lung cancer

The artificial intelligence and machine learning in lung cancer immunotherapy

A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts ALK Rearrangement Status in Lung Adenocarcinoma

Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC

Advances in artificial intelligence to predict cancer immunotherapy efficacy

Establishment and Evaluation of EGFR Mutation Prediction Model Based on Tumor Markers and CT Features in NSCLC

Quantitative Biomarkers for Prediction of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer